혈액 유래 바이오마커 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 용도별, 기술별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Blood-based Biomarkers Market Summary

The global blood-based biomarkers market size was valued at USD 8.7 billion in 2025 and is projected to grow from USD 9.3 billion in 2026 to USD 15.3 billion by 2033, at a CAGR of 7.4% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 42.6% in 2025. The market is driven by the growing adoption of precision medicine, increasing use of minimally invasive diagnostics, and advancements in molecular diagnostic technologies such as NGS and digital PCR.

Furthermore, the rising burden of cancer and neurological disorders, along with the integration of multi-omics platforms and AI-based biomarker analysis, is supporting broader clinical adoption of blood-based biomarkers.

Global Blood-based Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood-based biomarkers market report based on type, application, technology, end use, and region.

• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Genetic Biomarkers
• Protein Biomarkers
• Metabolic Biomarkers
• Cell-Based Biomarkers
• Epigenetic Biomarkers
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Others
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Immunoassays
• Mass Spectrometry
• Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Technology
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type, application, technology, and end use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood Based Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Advancements in biomarker technology
    • 3.2.1.3. Expanding research and funding support
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High development and validation costs
    • 3.2.2.2. Lack of reimbursement policies for biomarker treatment
• 3.3. Blood Based Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Environmental landscape

Chapter 4. Blood Based Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Global Blood Based Biomarkers Market: Type Dashboard
• 4.2. Global Blood Based Biomarkers Market: Type Movement Analysis
• 4.3. Global Blood Based Biomarkers Market by Type, Revenue
• 4.4. Genetic Biomarkers
  • 4.4.1. Genetic Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.5. Protein Biomarkers
  • 4.5.1. Protein Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.6. Metabolic Biomarkers
  • 4.6.1. Metabolic Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.7. Cell-Based Biomarkers
  • 4.7.1. Cell-Based Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.8. Epigenetic Biomarkers
  • 4.8.1. Epigenetic Biomarkers market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Blood Based Biomarkers Market: Application Estimates & Trend Analysis

• 5.1. Global Blood Based Biomarkers Market: Application Dashboard
• 5.2. Global Blood Based Biomarkers Market: Application Movement Analysis
• 5.3. Global Blood Based Biomarkers Market by Application , Revenue
• 5.4. Cancer
  • 5.4.1. Cancer market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.5. Cardiovascular Diseases
  • 5.5.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.6. Neurological Diseases
  • 5.6.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.7. Immunological Diseases
  • 5.7.1. Immunological diseases market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 6. Blood Based Biomarkers Market: Technology Estimates & Trend Analysis

• 6.1. Global Blood Based Biomarkers Market: Technology Dashboard
• 6.2. Global Blood Based Biomarkers Market: Technology Movement Analysis
• 6.3. Global Blood Based Biomarkers Market by Technology , Revenue
• 6.4. Next-Generation Sequencing
  • 6.4.1. Next-Generation Sequencing market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.5. Polymerase Chain Reaction
  • 6.5.1. Polymerase Chain Reaction market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.6. Immunoassays
  • 6.6.1. Immunoassays market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.7. Mass Spectrometry
  • 6.7.1. Mass Spectrometry market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.8. Others
  • 6.8.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 7. Blood Based Biomarkers Market: End Use Estimates & Trend Analysis

• 7.1. Global Blood Based Biomarkers Market: End Use Dashboard
• 7.2. Global Blood Based Biomarkers Market: End Use Movement Analysis
• 7.3. Global Blood Based Biomarkers Market by End Use, Revenue
• 7.4. Hospitals & Clinics
  • 7.4.1. Hospitals & clinics market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.5. Diagnostic Laboratories
  • 7.5.1. Diagnostic laboratories market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.6. Research & Academic Institutes
  • 7.6.1. Research & academic institutes market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.7. Others
  • 7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 8. Blood Based Biomarkers Market: Regional Estimates & Trend Analysis by Type, Application, Technology, and End Use

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Billion)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Billion)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Billion)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Billion)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Billion)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2024
  • 9.3.4. Abbott
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. BIOMERIEUX
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. F. Hoffmann-La Roche Ltd.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Siemens Healthineers AG
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Thermo Fisher Scientific, Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Bio-Rad Laboratories, Inc
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Cleveland Diagnostics, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Sysmex Corporation
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives